Webinar: Use of RNAscope ISH Services for T Cell Therapy Detection & Quantification

Webinar Summary

2020 Dec 15 PAS Webinar: Use of RNAscope ISH Services for T Cell Therapy Detection & Quantification

Presented by:
Christopher Bunker, Ph.D., MBA
Senior Director, Business Development,
Advanced Cell Diagnostics, a Bio-Techne Brand

Outline:
T Cell Therapy Detection and Quantification in Solid Tumors by RNAscope™ in situ hybridization.

RNAscope in situ hybridization (ISH) is the only method for specific detection of engineered CAR-T and TCR-T cell therapies in clinical trial patient biopsies.  IHC is unable to differentiate engineered T cells from endogenous cells. However, RNAscope probes targeting viral untranslated regions (UTRs) common to CAR and TCR mRNAs, enable specific detection and quantification of CAR/TCR-T cells in the tumor microenvironment (TME). RNAscope UTR probes are easily multiplexed with probes to assess activation, e.g., IFNG and GZMB, as well as with T cell IHC markers, e.g., CD3, CD4, CD8 to measure T cell recruitment. These assays are used to monitor T cell therapies in post-treatment patient biopsies and in preclinical animal models of safety and efficacy.

Key advantages of RNAscope cell therapy assays:

  • Simultaneously detect CAR/TCR-T cells with cytokines, immune cell markers and target antigens
  • Quantification of cell therapy tumor and stromal distribution and T cell recruitment
  • Patient biopsy analysis to link cell therapy pharmacokinetics/pharmacodynamics and efficacy.